The Hospital for Sick Children, Division for Haematology/Oncology, Toronto, Canada.
Future Oncol. 2009 Nov;5(9):1349-61. doi: 10.2217/fon.09.119.
High-grade gliomas and diffuse brainstem gliomas carry a very poor prognosis despite current therapies, and account together for the largest number of deaths in children with brain tumors. Many of these tumors have been found to overexpress the EGF receptor (EGFR). Nimotuzumab (h-R3) is a humanized monoclonal antibody against the EGFR, and consequently inhibits tyrosine kinase activation. In vitro and in vivo studies have supported the antiproliferative, antiangiogenic, pro-apoptotic and radiosensitizing activities of nimotuzumab. Emerging trials suggest a promising role for nimotuzumab as a therapeutic agent in patients with high-grade gliomas. This review attempts to provide a context for the evolving interest and evidence for nimotuzumab in pediatric glioma.
尽管目前有多种治疗方法，但高级别胶质瘤和弥漫性脑干胶质瘤的预后仍很差，它们共同导致了脑瘤患儿死亡人数最多。这些肿瘤中有许多被发现过度表达表皮生长因子受体（EGFR）。尼莫珠单抗（h-R3）是人源化针对 EGFR 的单克隆抗体，因此可抑制酪氨酸激酶的激活。体外和体内研究均支持尼莫珠单抗的抗增殖、抗血管生成、促凋亡和放射增敏作用。新出现的试验表明，尼莫珠单抗作为一种治疗药物在治疗高级别脑胶质瘤患者方面具有广阔的前景。本综述旨在为尼莫珠单抗在儿科脑胶质瘤中的应用提供一个不断发展的兴趣和证据背景。
